AANPCB Board Prep/Scientific Foundations
๐Ÿงฌ

Scientific Foundations

Neuroscience, neuroanatomy, genetics, pathophysiology of psychiatric disorders, and research literacy.

56 questions ยท AANPCB knowledge area

Practice Scientific Foundations Questions

Build a custom quiz and track your performance across AANPCB knowledge areas and process domains.

Build a Quiz

All 56 questions

1.
Serotonin Pathways and the Neuroscience of Depression
intermediateserotonindepressionmonoamine hypothesis
โ†’
2.
Dopamine Hypothesis of Schizophrenia and Antipsychotic Mechanisms
intermediatedopamineschizophreniaantipsychotics
โ†’
3.
GABAergic Mechanisms in Anxiety and Benzodiazepine Pharmacology
beginnerGABAanxietybenzodiazepines
โ†’
4.
HPA Axis Dysregulation and the Stress Response
advancedHPA axiscortisolCRH
โ†’
5.
Pharmacogenomics: CYP2D6 Poor Metabolizer Clinical Implications
advancedpharmacogenomicsCYP2D6poor metabolizer
โ†’
6.
Epigenetics and Adverse Childhood Experiences
intermediateepigeneticsadverse childhood experiencesDNA methylation
โ†’
7.
Sleep Architecture Stages and Psychiatric Implications
intermediatesleep architectureREM latencyslow-wave sleep
โ†’
8.
CYP3A4 Inducers and Psychiatric Drug Interactions
intermediateCYP3A4carbamazepinedrug interaction
โ†’
9.
Blood-Brain Barrier and Drug Lipophilicity
beginnerblood-brain barrierlipophilicitypharmacokinetics
โ†’
10.
Kindling Model in Bipolar Disorder Progression
intermediatekindlingbipolar disordermood stabilizer
โ†’
11.
Norepinephrine Pathways and the Locus Coeruleus in Anxiety
intermediatenorepinephrinelocus coeruleusPTSD
โ†’
12.
Acetylcholine and the Cholinergic Hypothesis of Alzheimer's Disease
beginneracetylcholineAlzheimer's diseasedonepezil
โ†’
13.
Endocannabinoid System and Psychiatric Relevance
advancedendocannabinoid systemCB1 receptorcannabis
โ†’
14.
Opioid Receptor Subtypes and Their Behavioral Effects
intermediateopioid receptorsbuprenorphinemethadone
โ†’
15.
Oxytocin and Social Bonding in Attachment Disorders
intermediateoxytocinattachmentsocial bonding
โ†’
16.
Inflammatory Cytokines and the Neuroinflammation Hypothesis of Depression
intermediateneuroinflammationcytokinesIDO
โ†’
17.
Default Mode Network and Rumination in Depression
advanceddefault mode networkruminationdepression
โ†’
18.
Reward Prediction Error and Dopamine Signaling in Addiction
advancedreward prediction errordopamineaddiction
โ†’
19.
Fear Conditioning and Extinction in Amygdala-Prefrontal Circuits
advancedfear conditioningextinctionamygdala
โ†’
20.
Hypothalamic-Pituitary-Gonadal Axis and Mood in Perimenopause
intermediateHPG axisestradiolperimenopause
โ†’
21.
Blood-Brain Barrier P-Glycoprotein and Psychotropic Drug Delivery
intermediateblood-brain barrierP-glycoproteinABCB1
โ†’
22.
First-Pass Metabolism and Oral Drug Bioavailability
beginnerfirst-pass metabolismbioavailabilitypharmacokinetics
โ†’
23.
Tolerance and Sensitization as Neuroadaptive Processes in Substance Use
intermediatetolerancesensitizationneuroadaptation
โ†’
24.
Sleep Stage Neurotransmitter Regulation and Psychiatric Medication Effects
beginnersleep architectureREM sleepserotonin-acetylcholine interaction
โ†’
25.
Neuroplasticity and BDNF in Antidepressant Response
intermediateneuroplasticityBDNFantidepressant
โ†’
26.
HPA Axis Dysregulation in PTSD
intermediateHPA axisPTSDcortisol
โ†’
27.
Glutamate NMDA Receptor Hypofunction in Schizophrenia
intermediateglutamateNMDA receptorschizophrenia
โ†’
28.
Epigenetics and the Impact of Early Adversity on Gene Expression
beginnerepigeneticsearly adversityACEs
โ†’
29.
Steady-State Pharmacokinetics and Half-Life in Clinical Dosing
beginnersteady statehalf-lifepharmacokinetics
โ†’
30.
CYP2C19 Polymorphisms and Escitalopram Dose Optimization
intermediateCYP2C19pharmacogenomicsescitalopram
โ†’
31.
Tuberoinfundibular Dopamine Pathway and Antipsychotic-Induced Hyperprolactinemia
intermediatetuberoinfundibular pathwayprolactindopamine
โ†’
32.
Thyroid Hormone Dysregulation and Psychiatric Symptom Mimicry
beginnerthyroidhypothyroidismdepression
โ†’
33.
Circadian Rhythm Neurobiology and Mood Disorder Pathophysiology
intermediatecircadian rhythmsuprachiasmatic nucleusbipolar disorder
โ†’
34.
Neurodevelopment: Prefrontal Cortex Maturation and Adolescent Risk-Taking
beginnerneurodevelopmentprefrontal cortexadolescent brain
โ†’
35.
Histamine H1 Receptor Antagonism: Sedation and Metabolic Effects of Psychotropics
intermediatehistamineH1 receptor5-HT2C
โ†’
36.
Research Literacy: Number Needed to Treat and Number Needed to Harm
beginnerNNTNNHresearch literacy
โ†’
37.
Receptor Pharmacology: Agonists, Antagonists, and Partial Agonists
intermediatepartial agonistreceptor pharmacologyaripiprazole
โ†’
38.
Psychiatric Genetics: Heritability and Polygenic Risk Architecture
intermediategeneticsheritabilitypolygenic risk
โ†’
39.
The Gut-Brain Axis: Enteric Serotonin and Microbiome-CNS Communication
intermediategut-brain axisserotoninmicrobiome
โ†’
40.
G-Protein Coupled Receptors and Second Messenger Signal Transduction
advancedGPCRsecond messengercAMP
โ†’
41.
Dementia with Lewy Bodies Differentiation
intermediateLewy body dementiaDLBvisual hallucinations
โ†’
42.
Narcolepsy Type 1 vs Type 2
intermediatenarcolepsycataplexysleep disorders
โ†’
43.
Frontotemporal Dementia, Behavioral Variant
intermediatefrontotemporal dementiabvFTDneurocognitive disorders
โ†’
44.
CYP2D6 Polymorphism and Pharmacogenomic Variability
hardCYP2D6pharmacogenomicsfluoxetine
โ†’
45.
GABA-A Receptor Subtypes and Anxiolytic Selectivity
hardGABA-A receptorbenzodiazepinealpha subunit
โ†’
46.
HPA Axis Dysregulation in Post-Traumatic Stress Disorder
hardHPA axisPTSDcortisol
โ†’
47.
Reward Circuitry in Substance Use Disorder
intermediatereward circuitryVTAnucleus accumbens
โ†’
48.
Serotonin Syndrome Pathophysiology and Receptor Mechanisms
intermediateserotonin syndrome5-HT1A5-HT2A
โ†’
49.
Blood-Brain Barrier Permeability and Drug Lipophilicity
intermediateblood-brain barrierlipophilicityP-glycoprotein
โ†’
50.
Norepinephrine Pathways and Anxiety Response
intermediatenorepinephrinelocus coeruleusanxiety
โ†’
51.
Cholinergic System and Cognitive Decline
intermediateacetylcholineAlzheimer's diseasenucleus basalis of Meynert
โ†’
52.
Kindling Model in Bipolar Illness Progression
intermediatekindling theorybipolar disorderillness progression
โ†’
53.
Stress-Diathesis Model and Psychiatric Vulnerability
intermediatestress-diathesisgene-environment interactionpsychosis
โ†’
54.
HLA-B*1502 Screening and Carbamazepine Risk
intermediatepharmacogenomicsHLA-B*1502carbamazepine
โ†’
55.
Assessing Serotonin Syndrome Clinical Features
hardserotonin syndromeneuroleptic malignant syndrometoxidrome
โ†’
56.
Assessing for Lithium Toxicity Signs
hardlithium toxicitydrug interactionthiazide diuretics
โ†’

Other AANPCB knowledge areas

๐Ÿ’Š Pharmacologyโšก Nonpharmacological Therapies๐Ÿ—ฃ๏ธ Psychotherapies๐Ÿ” Assessment & Diagnosis๐Ÿ“‹ Care Practices๐Ÿ“Œ Professional Role
โ† AANPCB Board Prep